BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Amortizatization of Intangibles of $56000.0 in Q1 2026, down 33.33% quarter-over-quarter from $84000.0 in Q4 2025, and down 29.11% on a YoY basis from $79000.0 in Q1 2025.
BioXcel Therapeutics (BTAI) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
BioXcel Therapeutics' Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $56000.0 for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 29.11% year-over-year to $56000.0; the TTM figure through Mar 2026 stood at $303000.0 (down 2.26% YoY), while the FY2025 annual figure was $326000.0, up 6.54% from the prior year.
- Amortizatization of Intangibles was $56000.0 for Q1 2026 at BioXcel Therapeutics, down from $84000.0 in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $84000.0 in Q4 2025 to a low of $56000.0 in Q1 2026.
- Historically, Amortizatization of Intangibles has averaged $75076.9 across 4 years, with a median of $75000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles gained 8.0% in 2025, then declined 29.11% in 2026.
- A 4-year view of Amortizatization of Intangibles shows it stood at $74000.0 in 2023, then climbed by 6.76% to $79000.0 in 2024, then rose by 6.33% to $84000.0 in 2025, then sank by 33.33% to $56000.0 in 2026.
- The last three Amortizatization of Intangibles figures came in at $56000.0 (Q1 2026), $84000.0 (Q4 2025), and $82000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | - |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 1.30 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | - |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | 242,000.00 |
| 10 | BioXcel Therapeutics | 25.81 Mn | 25.81 Mn | -77,000.00 | 56,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56,000.00 |
| Mar 31, 2026 | 56,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Dec 31, 2025 | 84,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Sep 30, 2025 | 82,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Mar 31, 2025 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Dec 31, 2024 | 79,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Sep 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Jun 30, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Dec 31, 2023 | 74,000.00 |